Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ONC BeOne Medicines	$320.10 -4.7%	$322.00	$170.99 ▼ $355.30	$35.08B	0.31	407,954 shs	335,035 shs
PFE Pfizer	$24.81 -1.7%	$24.83	$20.92 ▼ $29.82	$141.03B	0.55	46.93 million shs	64.26 million shs
TAK Takeda Pharmaceutical	$13.73 -2.5%	$14.87	$12.80 ▼ $15.69	$43.69B	0.21	2.60 million shs	2.95 million shs
VTRS Viatris	$9.74 -2.5%	$10.05	$6.85 ▼ $13.55	$11.36B	0.9	12.30 million shs	7.66 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ONC BeOne Medicines	-4.36%	-2.71%	-4.37%	+34.16%	+33,579,999,900.00%
PFE Pfizer	-1.75%	-6.85%	+1.94%	-1.68%	-16.48%
TAK Takeda Pharmaceutical	-1.54%	-2.25%	-7.72%	-3.89%	-1.23%
VTRS Viatris	+0.20%	-1.19%	-4.40%	+9.54%	-12.45%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ONC BeOne Medicines	$320.10 -4.7%	$322.00	$170.99 ▼ $355.30	$35.08B	0.31	407,954 shs	335,035 shs
PFE Pfizer	$24.81 -1.7%	$24.83	$20.92 ▼ $29.82	$141.03B	0.55	46.93 million shs	64.26 million shs
TAK Takeda Pharmaceutical	$13.73 -2.5%	$14.87	$12.80 ▼ $15.69	$43.69B	0.21	2.60 million shs	2.95 million shs
VTRS Viatris	$9.74 -2.5%	$10.05	$6.85 ▼ $13.55	$11.36B	0.9	12.30 million shs	7.66 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ONC BeOne Medicines	-4.36%	-2.71%	-4.37%	+34.16%	+33,579,999,900.00%
PFE Pfizer	-1.75%	-6.85%	+1.94%	-1.68%	-16.48%
TAK Takeda Pharmaceutical	-1.54%	-2.25%	-7.72%	-3.89%	-1.23%
VTRS Viatris	+0.20%	-1.19%	-4.40%	+9.54%	-12.45%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ONC BeOne Medicines	2.90	Moderate Buy	$340.30	4.75% Upside
PFE Pfizer	2.37	Hold	$28.35	13.07% Upside
TAK Takeda Pharmaceutical	2.00	Hold	N/A	N/A
VTRS Viatris	1.67	Reduce	$10.40	5.64% Upside

Current Analyst Ratings Breakdown

Latest VTRS, PFE, TAK, and ONC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/10/2025	PFE Pfizer	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$32.00
10/8/2025	ONC BeOne Medicines	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$345.00 ➝ $385.00
10/8/2025	ONC BeOne Medicines	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
10/8/2025	PFE Pfizer	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C-)
10/8/2025	VTRS Viatris	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
10/3/2025	PFE Pfizer	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$28.00 ➝ $30.00
10/1/2025	PFE Pfizer	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$28.00
9/27/2025	ONC BeOne Medicines	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/27/2025	PFE Pfizer	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C-)
9/27/2025	TAK Takeda Pharmaceutical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
9/27/2025	VTRS Viatris	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)

(Data available from 10/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ONC BeOne Medicines	$3.81B	9.35	N/A	N/A	$34.10 per share	9.53
PFE Pfizer	$63.63B	2.24	$4.26 per share	5.88	$15.62 per share	1.61
TAK Takeda Pharmaceutical	$4.48T	0.01	$3.06 per share	4.50	$14.39 per share	0.96
VTRS Viatris	$14.12B	0.81	$5.02 per share	1.96	$15.61 per share	0.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ONC BeOne Medicines	-$644.79M	-$1.73	N/A	457.58	N/A	-3.89%	-1.22%	-0.72%	N/A
PFE Pfizer	$8.03B	$1.88	13.35	8.28	0.84	16.84%	21.42%	9.12%	11/4/2025 (Estimated)
TAK Takeda Pharmaceutical	$712.33M	$0.30	45.92	8.34	N/A	3.20%	10.50%	5.10%	10/30/2025 (Estimated)
VTRS Viatris	-$634.20M	-$2.90	N/A	3.83	N/A	-24.57%	16.54%	7.06%	11/6/2025 (Estimated)

Latest VTRS, PFE, TAK, and ONC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/6/2025	Q3 2025	VTRS Viatris	$0.63	N/A	N/A	N/A	$3.60 billion	N/A
11/4/2025	Q3 2025	PFE Pfizer	$0.79	N/A	N/A	N/A	$16.94 billion	N/A
10/30/2025	Q2 2026	TAK Takeda Pharmaceutical	$0.46	N/A	N/A	N/A	$8.01 billion	N/A
8/7/2025	Q2 2025	VTRS Viatris	$0.56	$0.62	+$0.06	N/A	$3.46 billion	$3.58 billion
8/6/2025	Q2 2025	ONC BeOne Medicines	$0.48	$0.84	+$0.36	$0.84	$1.24 billion	$1.32 billion
8/5/2025	Q2 2025	PFE Pfizer	$0.58	$0.78	+$0.20	$0.51	$13.43 billion	$14.65 billion
7/30/2025	Q1 2026	TAK Takeda Pharmaceutical	$0.47	$0.52	+$0.05	$0.27	$7.96 billion	$7.45 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ONC BeOne Medicines	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	6.86%	N/A	91.49%	16 Years
TAK Takeda Pharmaceutical	$0.55	4.00%	N/A	183.33%	N/A
VTRS Viatris	$0.48	4.88%	N/A	N/A	N/A

Latest VTRS, PFE, TAK, and ONC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
10/9/2025	PFE Pfizer	quarterly	$0.43	6.82%	11/7/2025	11/7/2025	12/1/2025
8/4/2025	VTRS Viatris	quarterly	$0.12	5.37%	8/22/2025	8/22/2025	9/15/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ONC BeOne Medicines	0.04	1.95	1.72
PFE Pfizer	0.65	1.16	0.85
TAK Takeda Pharmaceutical	0.60	1.16	0.59
VTRS Viatris	0.94	1.37	0.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ONC BeOne Medicines	48.55%
PFE Pfizer	68.36%
TAK Takeda Pharmaceutical	9.17%
VTRS Viatris	79.88%

Insider Ownership

Company	Insider Ownership
ONC BeOne Medicines	6.62%
PFE Pfizer	0.06%
TAK Takeda Pharmaceutical	0.04%
VTRS Viatris	0.13%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ONC BeOne Medicines	11,000	109.60 million	102.34 million	N/A
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable
TAK Takeda Pharmaceutical	47,455	3.18 billion	3.18 billion	Optionable
VTRS Viatris	32,000	1.17 billion	1.16 billion	Optionable

VTRS, PFE, TAK, and ONC Headlines

Recent News About These Companies

Viatris Named to Forbes' Annual List of the World's Best Employers for the Fifth Year in a Row

October 8 at 11:00 AM | prnewswire.com

Viatris shares break six-session winning streak

October 7 at 11:05 AM | msn.com

Viatris to Report Third Quarter 2025 Financial Results on November 6, 2025

October 1, 2025 | prnewswire.com

Is Viatris Stock Underperforming the Nasdaq?

September 26, 2025 | msn.com

Viatris: Indore Plant Could Boost 2026 Numbers

September 25, 2025 | seekingalpha.com

Viatris Inc. (VTRS) Gains FDA Approval for First Generic Iron Sucrose Injection

September 25, 2025 | finance.yahoo.com

Viatris Inc. (VTRS) Gains FDA Approval for First Generic Iron Sucrose Injection

September 24, 2025 | msn.com

Viatris Inc. (VTRS) Enters $515M IV Iron Market With FDA Green Light

September 17, 2025 | finance.yahoo.com

Mapi Pharma Announces First Patient Recruited in Phase-I/II Study of Cariprazine Depot Once Monthly Injection

September 17, 2025 | markets.businessinsider.com

Viatris rises after a steep seven-day slide

September 17, 2025 | msn.com

Viatris Inc. (VTRS) Enters $515M IV Iron Market With FDA Green Light

September 16, 2025 | msn.com

1 Unprofitable Stock with Impressive Fundamentals and 2 That Underwhelm

September 8, 2025 | finance.yahoo.com

1 Volatile Stock on Our Buy List and 2 Facing Challenges

September 4, 2025 | finance.yahoo.com

Insider Watch: 3 CEOs Buying the Dip

September 3, 2025 | zacks.com

Will Viatris’ (VTRS) New Transformation Role Accelerate Its Operational and Cultural Overhaul?

August 30, 2025 | finance.yahoo.com

Viatris, Inc. (VTRS) Achieves Key Clinical Milestones in Ophthalmology, Pain, Women’s Health

August 29, 2025 | finance.yahoo.com

22 S&P 500 stocks have lost money over the past decade

August 26, 2025 | msn.com

3 Stocks Under $50 Walking a Fine Line

August 25, 2025 | msn.com

Viatris Inc.: Viatris Appoints Andrew Enrietti as Chief Administrative and Transformation Officer

August 19, 2025 | finanznachrichten.de

Viatris names Andrew Enrietti Chief Administrative and Transformation Officer

August 19, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

VTRS, PFE, TAK, and ONC Company Descriptions

BeOne Medicines NASDAQ:ONC

$320.10 -15.70 (-4.68%)

As of 04:00 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Pfizer NYSE:PFE

$24.80 -0.44 (-1.72%)

Closing price 03:59 PM Eastern

Extended Trading

$24.46 -0.34 (-1.37%)

As of 05:43 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Takeda Pharmaceutical NYSE:TAK

$13.73 -0.35 (-2.49%)

Closing price 03:59 PM Eastern

Extended Trading

$14.16 +0.43 (+3.13%)

As of 05:15 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Viatris NASDAQ:VTRS

$9.74 -0.25 (-2.50%)

Closing price 04:00 PM Eastern

Extended Trading

$9.64 -0.10 (-0.98%)

As of 05:40 PM Eastern

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VTRS, PFE, TAK, and ONC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VTRS, PFE, TAK, and ONC Earnings

Compare Dividends

Latest VTRS, PFE, TAK, and ONC Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VTRS, PFE, TAK, and ONC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

VTRS, PFE, TAK, and ONC Company Descriptions

BeOne Medicines NASDAQ:ONC

Pfizer NYSE:PFE

Takeda Pharmaceutical NYSE:TAK

Viatris NASDAQ:VTRS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools